Abstract: Journal of Clinical Medicine Article Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020 Fabien Taieb 1, *, Khardiata Diallo Mbaye 2 , Billo Tall 1 , Ndèye Aïssatou Lakhe 2 , Cheikh Talla 1 , Daouda Thioub 2 , Amadou Moustapha Ndoye 1 , Daye Ka 2 , Aboubacry Gaye 1 , Viviane Marie-Pierre Cissé Diallo 2 , Ndongo Dia 1 , Pape Samba Ba 3 , Mamadou Cissé 1 , Moustapha Diop 3 , Cheikh Tidiane Diagne 1 , Louise Fortes 2,4 , Mamadou Diop 1 , Ndèye Maguette Fall 2,5 , Fatoumata Diène Sarr 1 , Margarite Diatta 1 , Mamadou Aliou Barry 1 , Aboubakar Sidikh Badiane 2,6 , Abdoulaye Seck 1 , Philippe Dubrous 1 , Ousmane Faye 1 , Inès Vigan-Womas 1 , Cheikh Loucoubar 1 , Amadou Alpha Sall 1 and Moussa Seydi 2 1



 Citation: Taieb, F.; Mbaye, K.D.; Tall, 2 B.; Lakhe, N.A.; Talla, C.; Thioub, D.; Ndoye, A.M.; Ka, D.; Gaye, A.; Cissé Diallo, V.M.-P.; et al. Hydroxychloroquine and 3 Azithromycin Treatment of Hospitalized Patients Infected with 4 SARS-CoV-2 in Senegal from March 5 to October 2020. J. Clin. Med. 2021, 10, Institut Pasteur de Dakar, Dakar BP 220, Senegal; billo.tall@pasteur.sn (B.T.); ctalla@pasteur.sn (C.T.); amadoumoustapha.ndoye@pasteur.sn (A.M.N.); aboubacry.gaye@pasteur.sn (A.G.); ndongo.dia@pasteur.sn (N.D.); mamadou.cisse@pasteur.sn (M.C.); CheikhTidiane.DIAGNE@pasteur.sn (C.T.D.); mamadou.diop@pasteur.sn (M.D.); fatoumata.sarr@pasteur.sn (F.D.S.); Marguerite.diatta@pasteur.sn (M.D.); aliou.barry@pasteur.sn (M.A.B.); ablayseck@gmail.com (A.S.); Philippe.dubrous@pasteur.sn (P.D.); Ousmane.faye@pasteur.sn (O.F.); Ines.vigan-womas@pasteur.sn (I.V.-W.); cheikh.loucoubar@pasteur.sn (C.L.); Amadou.sall@pasteur.sn (A.A.S.) Service des Maladies Infectieuses et Tropicales, De Fann University Hospital Center (CNHU FANN), Dakar BP 5035, Senegal; diallokhardiata@gmail.com (K.D.M.); aissatoulakhe@gmail.com (N.A.L.); dave11690@gmail.com (D.T.); dayeka10@gmail.com (D.K.); vivich6@gmail.com (V.M.-P.C.D.); louisefortes@gmail.com (L.F.); maguifall4@gmail.com (N.M.F.); aboubakrbadiane@yahoo.fr (A.S.B.); seydim@u.washington.edu (M.S.) Hôpital Principal de Dakar, Dakar BP 220, Senegal; basambasn2000@yahoo.fr (P.S.B.); mouztaphandm@gmail.com (M.D.) Centre de Traitement des épidémies de l’Hôpital Dalal Jamm, Dakar BP 19.001, Senegal Hôpital de Diamnadio, Centre de Traitement des épidémies de l’Hôpital de Diamnadio, Bargny BP 204, Senegal Fann University Hospital, Centre de Traitement des épidémies de Touba, Touba 22300, Senegal Correspondence: fabien.taieb@pasteur.sn 2954. https://doi.org/10.3390/ 6 jcm10132954 * Academic Editors: Philippe Parola, Abstract: As of today, little data is available on COVID-19 in African countries, where the case management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19 hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus AZM and those who did not receive this combination. A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the..